If this message is not displayed correctly, click here.


No 112, September 2017


A new NDT-Educational Summary Report of the 54th ERA-EDTA Congress is now available on ENP!

A new NDT-Educational Summary Report of 54th ERA-EDTA Congress (Madrid, Spain) based on Prof. Raymond Vanholder's presentation “Metabolomics and-or Uremic Toxins” is now online! Click here to read it.

Prof. Quirino Maggiore

In memory of Prof. Quirino Maggiore

The ERA-EDTA is mourning the loss of Prof. Quirino Maggiore, a renowned representative of European Nephrology.

A very evocative interview to Prof. Maggiore is included in the ‘Pioneers of Nephrology’ project which consists in a number of interviews done by Dr Giorgina Piccoli with the help of the film-maker and musician Gilberto Richiero.
Click here to watch the video.

The ERA-EDTA Council and the whole Association would like honour the life and achievements of Prof. Quirino Maggiore with an In Memoriam tribute written by Prof. Carmine Zoccali.

NDT and CKJ articles

Just published online! Read the latest NDT and CKJ articles

Really nothing to worry about? Long-term outcome in patients with benign IgAN is often not considered

Patients with immunoglobulin A nephropathy (IgAN) with mild to moderate proteinuria and normal renal function are assumed to have excellent short-term renal prognosis. Long-term prognosis is also believed to be quite good in these patients, but this might be misleading. A study has now been published in NDT in which the long-term outcomes of 145 patients selected from the Norwegian Kidney Biopsy Registry were analyzed. A ≥50% decrease in eGFR was seen in 2.1% of the patients after 10 years, in 4.1% after 15 years, in 13.9% after 20 years and in 24.7% after 25 years. This shows that nearly one out of four patients with good prognosis suffered from a severe decrease in kidney function after 25 years. This shows that these patients, who are usually young when diagnosed with IgAN, are at risk of becoming ESRD patients two and a half decades later. Therefore, according to the authors of the study, an extended follow-up period is needed when assessing prognosis in this group of patients.

Tricky in Everyday Practice: Pain Management in CKD Patients

Although kidney diseases are more or less painless, many CKD patients suffer from pain due to other reasons – e.g. from musculoskeletal pain. The incidence of pain in patients who receive renal replacement therapy is about 40-60% - comparable to that of the general population of similar age. Pain management is often a challenge in CKD patients due to altered drug pharmacokinetics and various physiological aspects associated with reduced kidney function. Increased drug levels and associated adverse effects may occur due to reduced renal clearance. Some therapies are also clearly contraindicated, which limits treatment options. NSAIDs are known to have direct nephrotoxic effects leading to reduced glomerular filtration (whenever NSAIDs use must be considered due to the lack of effective alternatives, short-acting agents are preferred over long-acting ones), opioids are even potentially life-threatening in this subpopulation. On the other hand suboptimal pain control is associated with poor quality of life, depression and possibly lower long-term survival. The article by Pham et al. published in CKJ gives a detailed overview on pain management in kidney patients.


EURECA-m for the care of patients affected by renal cardiovascular diseases

The EUropean REnal and CArdiac medicine (EURECA-m) Working Group was the first working group approved by the ERA-EDTA Council (2009). So far, EURECA-m has published 19 papers in well renowned journals like The Lancet (3), Hypertension (3), Nature (3), AJKD (1) and of course NDT (9). EURECA-m is also committed to research projects. EURECA-m launched the ERA-EDTA funded LUST study focusing on the role of lung ultrasound to measure lung water and pulmonary congestion. EURECA-m also started the EURECA-m Registry (2011).

This year the EURECA-m CME will be held in Taormina (Italy) on October 2, 2017 and it is designed to be a brainstorming meeting covering crucial topics related to the management of patients affected by renal cardiovascular diseases. The meeting consists in four sessions: Session 1 – At the core of CKD: Energy, metabolism and Inflammation; Session 2 – Countering CKD in 2017. Hope, disappointment and progress in basic science; Session 3 – Focus on the cardio-renal link and hypertension; Session 4 – How can we counter the dim prognosis of end stage kidney disease (ESKD)?

The deadline for registrations is September 20, 2017.

Web Site

ERA-EDTA Flash is the official ERA-EDTA eNewsletter

Editor-in-Chief: Mustafa Arici
Editorial Secretariat: Valentina Cocchi
Newsletter Design: Ilaria Martini

ERA-EDTA Headquarters
Via XXIV Maggio, 38
43123 Parma - Italy


he ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the Italian Legislative Decree 196/2003.